Literature DB >> 27478197

Recent frustration and innovation in myelodysplastic syndrome.

Uwe Platzbecker1, Pierre Fenaux2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27478197      PMCID： PMC4967566          DOI： 10.3324/haematol.2016.142836

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

2.  Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?

Authors:  Uwe Platzbecker; Pierre Fenaux
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

3.  Clonal hematopoiesis and blood-cancer risk.

Authors:  Giulio Genovese; Siddhartha Jaiswal; Benjamin L Ebert; Steven A McCarroll
Journal:  N Engl J Med       Date:  2015-03-12       Impact factor: 91.245

4.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

Review 5.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

6.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Authors:  A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

7.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

Authors:  Guillermo Garcia-Manero; Pierre Fenaux; Aref Al-Kali; Maria R Baer; Mikkael A Sekeres; Gail J Roboz; Gianluca Gaidano; Bart L Scott; Peter Greenberg; Uwe Platzbecker; David P Steensma; Suman Kambhampati; Karl-Anton Kreuzer; Lucy A Godley; Ehab Atallah; Robert Collins; Hagop Kantarjian; Elias Jabbour; Francois E Wilhelm; Nozar Azarnia; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2016-03-09       Impact factor: 41.316

8.  A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.

Authors:  Kenneth M Attie; Mark J Allison; Ty McClure; Ingrid E Boyd; Dawn M Wilson; Amelia E Pearsall; Matthew L Sherman
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

9.  Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.

Authors:  Rajasekhar N V S Suragani; Samuel M Cadena; Sharon M Cawley; Dianne Sako; Dianne Mitchell; Robert Li; Monique V Davies; Mark J Alexander; Matthew Devine; Kenneth S Loveday; Kathryn W Underwood; Asya V Grinberg; John D Quisel; Rajesh Chopra; R Scott Pearsall; Jasbir Seehra; Ravindra Kumar
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.